A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Shen, Jie ^a   Wei, Jia ^a   Wang, Hao ^a   Yue, Guofeng ^b   Yu, Lixia ^a   Yang, Yang ^a   Xie, Li ^a   Zou, Zhengyun ^a   Qian, Xiaoping ^a   Ding, Yitao ^a   Guan, Wenxian ^a   Liu, Baorui ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Gastric cancer; HDRA; Immunodeficient mice; Irinotecan; Personalized chemotherapy

Indexed keywords

BRCA1 PROTEIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; IRINOTECAN; PROTEIN APTX; PROTEIN ISG15; PROTEIN SULF2; PROTEIN TOPO1; TUMOR MARKER; UNCLASSIFIED DRUG; CAMPTOTHECIN; SULF2 PROTEIN, HUMAN; SULFOTRANSFERASE; TUMOR PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CANCER TISSUE; CONTROLLED STUDY; DNA METHYLATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PROGNOSIS; STOMACH CANCER; ANALOGS AND DERIVATIVES; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHYLATION; MIDDLE AGED; REPRODUCIBILITY; STOMACH NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CAMPTOTHECIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; METHYLATION; MICE; MIDDLE AGED; MODELS, GENETIC; NEOPLASM PROTEINS; REPRODUCIBILITY OF RESULTS; STOMACH NEOPLASMS; SULFOTRANSFERASES; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875133213     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-73     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006, 24:2903-2909. 10.1200/JCO.2005.05.0245, 16782930.
3. Kubota T. New chemotherapy strategies for gastric cancer. In Vivo 2008, 22:273-278.
4. Wesolowski R, Lee C, Kim R. Is there a role for second-line chemotherapy in advanced gastric cancer?. Lancet Oncol 2009, 10:903-912. 10.1016/S1470-2045(09)70136-6, 19717092.
5. Farhat FS. A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer. Med Oncol 2007, 24:137-146. 10.1007/BF02698032, 17848736.
6. Schilsky RL. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 2010, 9:363-366. 10.1038/nrd3181, 20431568.
7. Wei J, Costa C, Ding Y, Zou Z, Yu L, Sanchez JJ, Qian X, Chen H, Gimenez-Capitan A, Meng F. mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. J Natl Cancer Inst 2011, 103:1552-1556. 10.1093/jnci/djr326, 21862729.
8. Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu L, Wang T, Liu B. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 2008, 8:97. 10.1186/1471-2407-8-97, 2394535, 18402708.
9. Shen J, Wang H, Wei J, Yu L, Xie L, Qian X, Zou Z, Liu B, Guan W. Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer. Int J Cancer 2012, 131:E938-E945. 10.1002/ijc.27530, 22422354.
10. Wang L, Liu B, Wang T, Ding Y, Qian X, Zhao Y. Detection of cell-free ERCC1 and thymidylate synthase (TS) mRNA in malignant effusions and its association with anticancer drug sensitivity. Anticancer Res 2008, 28:1085-1091.
11. Wei J, Zou Z, Qian X, Ding Y, Xie L, Sanchez JJ, Zhao Y, Feng J, Ling Y, Liu Y. ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer 2008, 98:1398-1402. 10.1038/sj.bjc.6604317, 2361707, 18362936.
12. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002, 13:1841-1851. 10.1093/annonc/mdf337, 12453851.
13. Dopeso H, Mateo-Lozano S, Elez E, Landolfi S, Ramos Pascual FJ, Hernandez-Losa J, Mazzolini R, Rodrigues P, Bazzocco S, Carreras MJ. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment. Clin Cancer Res 2010, 16:2375-2382. 10.1158/1078-0432.CCR-09-3275, 20371676.
14. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH, Selby P, Meade AM, Stephens RJ. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008, 26:2690-2698. 10.1200/JCO.2007.15.5580, 18509181.
15. Gilbert DC, Chalmers AJ, El-Khamisy SF. Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. Br J Cancer 2012, 106:18-24. 10.1038/bjc.2011.498, 3251848, 22108516.
16. Tessema M, Yingling CM, Thomas CL, Klinge DM, Bernauer AM, Liu Y, Dacic S, Siegfried JM, Dahlberg SE, Schiller JH, Belinsky SA. SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. Oncogene 2012, 31:4107-4116. 10.1038/onc.2011.577, 3307938, 22158045.
17. Desai SD, Haas AL, Wood LM, Tsai YC, Pestka S, Rubin EH, Saleem A, Nur EKA, Liu LF. Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. Cancer Res 2006, 66:921-928. 10.1158/0008-5472.CAN-05-1123, 16424026.
18. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995, 1:305-311.
19. Fujita Y, Hiramatsu M, Kawai M, Nishimura H, Miyamoto A, Tanigawa N. Histoculture drug response assay predicts the postoperative prognosis of patients with esophageal cancer. Oncol Rep 2009, 21:499-505.
20. Margeli M, Cirauqui B, Castella E, Tapia G, Costa C, Gimenez-Capitan A, Barnadas A, Sanchez Ronco M, Benlloch S, Taron M, Rosell R. The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer. PLoS One 2010, 5:e9499. 10.1371/journal.pone.0009499, 2831058, 20209131.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
22. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010, 28:1721-1726. 10.1200/JCO.2009.24.9342, 20194856.
23. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 2008, 14:6456-6468. 10.1158/1078-0432.CCR-08-0138, 18927285.
24. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007, 356:11-20. 10.1056/NEJMoa060096, 17202451.
25. Larsen JE, Pavey SJ, Passmore LH, Bowman RV, Hayward NK, Fong KM. Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res 2007, 13:2946-2954. 10.1158/1078-0432.CCR-06-2525, 17504995.
26. Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010, 28:1829-1834. 10.1200/JCO.2009.24.4798, 20212256.
27. Tanino H, Oura S, Hoffman RM, Kubota T, Furukawa T, Arimoto J, Yoshimasu T, Hirai I, Bessho T, Suzuma T. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay. Anticancer Res 2001, 21:4083-4086.
28. Ariyoshi Y, Shimahara M, Tanigawa N. Study on chemosensitivity of oral squamous cell carcinomas by histoculture drug response assay. Oral Oncol 2003, 39:701-707. 10.1016/S1368-8375(03)00082-4, 12907210.
29. Hasegawa Y, Goto M, Hanai N, Ijichi K, Adachi M, Terada A, Hyodo I, Ogawa T, Furukawa T. Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer. Oral Oncol 2007, 43:749-756. 10.1016/j.oraloncology.2006.09.003, 17112769.
30. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 2006, 66:3351-3354. discussion 3354, 10.1158/0008-5472.CAN-05-3627, 16585151.
31. Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007, 170:793-804. 10.2353/ajpath.2007.060929, 1864878, 17322365.
32. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH, Eshleman JR, Klein A, Laheru D. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 2011, 10:3-8. 3307340, 21135251.
33. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011, 10:1311-1316. 10.1158/1535-7163.MCT-11-0233, 21673092.
34. Ramaswamy S. Translating cancer genomics into clinical oncology. N Engl J Med 2004, 350:1814-1816. 10.1056/NEJMp048059, 15115827.
35. Mariadason JM, Arango D, Shi Q, Wilson AJ, Corner GA, Nicholas C, Aranes MJ, Lesser M, Schwartz EL, Augenlicht LH. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 2003, 63:8791-8812.
36. Zander SA, Kersbergen A, van der Burg E, de Water N, van Tellingen O, Gunnarsdottir S, Jaspers JE, Pajic M, Nygren AO, Jonkers J. Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res 2010, 70:1700-1710. 10.1158/0008-5472.CAN-09-3367, 20145144.
37. Kirschner K, Melton DW. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res 2010, 30:3223-3232.
38. Tessema M, Yu YY, Stidley CA, Machida EO, Schuebel KE, Baylin SB, Belinsky SA. Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. Carcinogenesis 2009, 30:1132-1138. 10.1093/carcin/bgp114, 2704285, 19435948.